This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Leading USA based genetic testing brand officially enters the Indian market
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Demonstrate significant bleed reduction in hemophilia A and B
New facility is part of Aptar Pharma’s global expansion program
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
This acquisition marks Max Healthcare's entry into Lucknow
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
